Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?

Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Clin Genitourin Cancer. 2019 May 24. pii: S1558-7673(18)30729-8. doi: 10.1016/j.clgc.2019.05.007. [Epub ahead of print]

PMID:
31257075
2.

Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate.

Budäus L, Schiffmann J, Graefen M, Huland H, Tennstedt P, Siegmann A, Böhmer D, Budach V, Bartkowiak D, Wiegel T.

Strahlenther Onkol. 2017 Sep;193(9):692-699. doi: 10.1007/s00066-017-1140-y. Epub 2017 May 3.

PMID:
28470414
3.

Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.

Bartkowiak D, Thamm R, Bottke D, Siegmann A, Böhmer D, Budach V, Wiegel T.

Acta Oncol. 2018 Mar;57(3):362-367. doi: 10.1080/0284186X.2017.1364869. Epub 2017 Aug 17.

PMID:
28816074
4.

The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.

Bartkowiak D, Bottke D, Thamm R, Siegmann A, Hinkelbein W, Wiegel T.

Radiother Oncol. 2016 Jan;118(1):131-5. doi: 10.1016/j.radonc.2015.10.028. Epub 2015 Nov 30.

PMID:
26653358
5.

Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Lee EK, Mui WH, Chan AW, Tung Y, Wong FC.

Hong Kong Med J. 2018 Jun;24(3):218-225. doi: 10.12809/hkmj176888. Epub 2018 May 21.

6.

Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.

Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.

J Nucl Med. 2017 Dec;58(12):1972-1976. doi: 10.2967/jnumed.117.196683. Epub 2017 Jul 26.

7.

Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.

Cortés-González JR, Castellanos E, Sandberg K, Eriksson MH, Wiklund P, Carlsson S, Cohn-Cedermark G, Harmenberg U, Gustafsson O, Levitt SH, Lennernäs B, Brandberg Y, Márquez M, Kälkner KM, Nilsson S.

Int J Oncol. 2013 Jan;42(1):109-17. doi: 10.3892/ijo.2012.1694. Epub 2012 Nov 13.

PMID:
23151842
8.

Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.

Bottke D, Bartkowiak D, Siegmann A, Thamm R, Böhmer D, Budach V, Wiegel T.

Prostate Cancer Prostatic Dis. 2019 May;22(2):344-349. doi: 10.1038/s41391-018-0112-3. Epub 2018 Nov 28.

PMID:
30487644
9.

The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer.

Bartkowiak D, Siegmann A, Böhmer D, Budach V, Wiegel T.

BJU Int. 2019 Jun 20. doi: 10.1111/bju.14851. [Epub ahead of print]

PMID:
31220400
10.

Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.

Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A.

Eur Urol. 2017 Aug 2. pii: S0302-2838(17)30655-3. doi: 10.1016/j.eururo.2017.07.026. [Epub ahead of print]

PMID:
28779974
11.

Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure.

Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK.

Pract Radiat Oncol. 2014 Nov-Dec;4(6):409-14. doi: 10.1016/j.prro.2014.01.002. Epub 2014 Feb 22.

PMID:
25407863
12.

Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.

Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ.

J Clin Oncol. 2016 Nov 10;34(32):3864-3871. doi: 10.1200/JCO.2016.68.3425.

PMID:
27480153
13.

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.

J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.

14.

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A.

J Clin Oncol. 2007 May 20;25(15):2035-41. Erratum in: J Clin Oncol. 2007 Sep 10;25(26):4153.

15.

Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.

Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1009-16. doi: 10.1016/j.ijrobp.2008.06.1922. Epub 2008 Oct 27.

PMID:
18963539
16.

Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.

Breeuwsma AJ, Rybalov M, Leliveld AM, Pruim J, de Jong IJ.

Q J Nucl Med Mol Imaging. 2012 Oct;56(5):440-6.

PMID:
23069923
17.

Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience.

Rodin D, Drumm M, Clayman R, Buscariollo DL, Galland-Girodet S, Eidelman A, Feldman AS, Dahl DM, McGovern FJ, Olumi AF, Niemierko A, Shipley WU, Zietman AL, Efstathiou JA.

Clin Genitourin Cancer. 2017 Aug 3. pii: S1558-7673(17)30236-7. doi: 10.1016/j.clgc.2017.07.026. [Epub ahead of print]

PMID:
28864223
18.

Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.

Geinitz H, Riegel MG, Thamm R, Astner ST, Lewerenz C, Zimmermann F, Molls M, Nieder C.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1930-7. doi: 10.1016/j.ijrobp.2011.03.003. Epub 2011 Apr 22.

PMID:
21514736
19.

Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.

Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML.

J Urol. 2004 Dec;172(6 Pt 1):2244-8.

PMID:
15538240
20.

Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey.

Lohm G, Lütcke J, Jamil B, Höcht S, Neumann K, Hinkelbein W, Wiegel T, Bottke D.

Strahlenther Onkol. 2014 Aug;190(8):727-31. doi: 10.1007/s00066-014-0612-6. Epub 2014 Feb 28.

PMID:
24577132

Supplemental Content

Support Center